HAVCR2 and acute myeloid leukemia: A recent study showed that CAR-T cells that were bispecific for CD13 and Tim-3 exhibited reduced toxicity to human bone marrow stem cells and peripheral myeloid cells in mouse models, which highlights a promising approach for the development of effective AML CAR-T cell therapy (69).